Zenas BioPharma reports Phase 3 INDIGO open-label extension obexelimab data in IgG4-RD

Zenas BioPharma, Inc.

12-month probability of remaining flare-free: 0.93 for adjudication committee-confirmed flares, 0.87 for investigator-determined; median cumulative glucocorticoid rescue dose 0 mg (mean 105 mg)
Obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference -11.4; p=0.021)
Vaccine sub-study: seroimmunity to influenza in 6 of 7 (86%) and COVID-19 in 4 of 4 (100%) during a treatment-free window averaging 34.6 days, with no disease flares
Participants (n=7) maintained pre-existing immunity markers after long-term obexelimab treatment: 71% for influenza and 50% for COVID-19
Data presented at the 6th International Symposium on IgG4-Related Disease, held October 8-10, 2026 in Cambridge, Massachusetts

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.